STOCK TITAN

[6-K] Medirom Healthcare Technologies Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

MEDIROM Healthcare Technologies Inc. (MRM) furnished a Form 6-K announcing it issued a press release about the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc.

The company notes this information is furnished, not filed, and is not incorporated by reference except as specifically provided. The press release is included as Exhibit 99.1.

MEDIROM Healthcare Technologies Inc. (MRM) ha fornito un modulo 6-K annunciando di aver emesso un comunicato stampa riguardante il round di finanziamento azionario Series A della sua sussidiaria MEDIROM MOTHER Labs Inc.

La società precisa che queste informazioni sono fornite e non depositate, e non sono incorporate per riferimento se non diversamente previsto. Il comunicato stampa è incluso come Allegato 99.1.

MEDIROM Healthcare Technologies Inc. (MRM) presentó un Formulario 6-K anunciando que emitió un comunicado de prensa sobre la ronda de financiación de capital Series A de su subsidiaria MEDIROM MOTHER Labs Inc.

La compañía señala que esta información se informa y no se presenta, y no se incorpora por referencia salvo que se indique expresamente. El comunicado de prensa se incluye como el Anexo 99.1.

MEDIROM Healthcare Technologies Inc. (MRM)는 자회사 MEDIROM MOTHER Labs Inc.의 Series A 주식 자금 조달 라운드에 관한 보도자료를 발표했다는 Form 6-K를 제출했습니다.

회사는 이 정보가 제출되었으며 등재된 것이 아니며 특별히 규정된 경우를 제외하고 참조에 의해 통합되지 않는다는 점을 주목합니다. 보도자료는 부록 99.1로 포함되어 있습니다.

MEDIROM Healthcare Technologies Inc. (MRM) a fourni un formulaire 6-K annonçant qu'il a publié un communiqué de presse concernant le tour de financement en actions de Series A de sa filiale, MEDIROM MOTHER Labs Inc.

La société précise que ces informations sont fournies et non déposées, et qu'elles ne sont pas intégrées par référence sauf indication contraire. Le communiqué de presse est inclus en tant que pièce jointe 99.1.

MEDIROM Healthcare Technologies Inc. (MRM) hat ein Form 6-K vorgelegt, in dem bekannt gegeben wird, dass ein Pressemitteilung über die Series-A-Eigenkapitalfinanzierungsrunde ihrer Tochtergesellschaft MEDIROM MOTHER Labs Inc. veröffentlicht wurde.

Das Unternehmen weist darauf hin, dass diese Informationen vorgelegt, nicht eingereicht sind und nicht per Verweis aufgenommen werden, außer wie ausdrücklich angegeben. Die Pressemitteilung ist als Anlage 99.1 enthalten.

قدمت شركة MEDIROM Healthcare Technologies Inc. (MRM) نموذج 6-K معلنة أنها أصدرت بياناً صحفياً حول جولة تمويل أسهم Series A لشركتها الفرعية MEDIROM MOTHER Labs Inc.

تلاحظ الشركة أن هذه المعلومات مُعدة وليس مُودعة، ولا تُدرج بالرجوع إليها إلا كما هو محدد بشكل خاص. البيان الصحفي مُدرج كمرفق 99.1.

Positive
  • None.
Negative
  • None.

MEDIROM Healthcare Technologies Inc. (MRM) ha fornito un modulo 6-K annunciando di aver emesso un comunicato stampa riguardante il round di finanziamento azionario Series A della sua sussidiaria MEDIROM MOTHER Labs Inc.

La società precisa che queste informazioni sono fornite e non depositate, e non sono incorporate per riferimento se non diversamente previsto. Il comunicato stampa è incluso come Allegato 99.1.

MEDIROM Healthcare Technologies Inc. (MRM) presentó un Formulario 6-K anunciando que emitió un comunicado de prensa sobre la ronda de financiación de capital Series A de su subsidiaria MEDIROM MOTHER Labs Inc.

La compañía señala que esta información se informa y no se presenta, y no se incorpora por referencia salvo que se indique expresamente. El comunicado de prensa se incluye como el Anexo 99.1.

MEDIROM Healthcare Technologies Inc. (MRM)는 자회사 MEDIROM MOTHER Labs Inc.의 Series A 주식 자금 조달 라운드에 관한 보도자료를 발표했다는 Form 6-K를 제출했습니다.

회사는 이 정보가 제출되었으며 등재된 것이 아니며 특별히 규정된 경우를 제외하고 참조에 의해 통합되지 않는다는 점을 주목합니다. 보도자료는 부록 99.1로 포함되어 있습니다.

MEDIROM Healthcare Technologies Inc. (MRM) a fourni un formulaire 6-K annonçant qu'il a publié un communiqué de presse concernant le tour de financement en actions de Series A de sa filiale, MEDIROM MOTHER Labs Inc.

La société précise que ces informations sont fournies et non déposées, et qu'elles ne sont pas intégrées par référence sauf indication contraire. Le communiqué de presse est inclus en tant que pièce jointe 99.1.

MEDIROM Healthcare Technologies Inc. (MRM) hat ein Form 6-K vorgelegt, in dem bekannt gegeben wird, dass ein Pressemitteilung über die Series-A-Eigenkapitalfinanzierungsrunde ihrer Tochtergesellschaft MEDIROM MOTHER Labs Inc. veröffentlicht wurde.

Das Unternehmen weist darauf hin, dass diese Informationen vorgelegt, nicht eingereicht sind und nicht per Verweis aufgenommen werden, außer wie ausdrücklich angegeben. Die Pressemitteilung ist als Anlage 99.1 enthalten.

قدمت شركة MEDIROM Healthcare Technologies Inc. (MRM) نموذج 6-K معلنة أنها أصدرت بياناً صحفياً حول جولة تمويل أسهم Series A لشركتها الفرعية MEDIROM MOTHER Labs Inc.

تلاحظ الشركة أن هذه المعلومات مُعدة وليس مُودعة، ولا تُدرج بالرجوع إليها إلا كما هو محدد بشكل خاص. البيان الصحفي مُدرج كمرفق 99.1.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number 001-39809

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F


INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Issuance of Press Release

On October 30, 2025, MEDIROM Healthcare Technologies Inc. (the “Company”) issued a press release relating to the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of the Company.

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

EXHIBIT INDEX

Exhibit No.

    

Description

99.1 

Press release of the Company


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIROM Healthcare Technologies Inc.

Date: October 30, 2025

By:

/s/ Fumitoshi Fujiwara

Name: Fumitoshi Fujiwara

Title: Chief Financial Officer


Medirom Healthcare Technologies Inc

NASDAQ:MRM

MRM Rankings

MRM Latest News

MRM Latest SEC Filings

MRM Stock Data

16.36M
5.81M
26.42%
1.43%
6.28%
Personal Services
Consumer Cyclical
Link
Japan
Tokyo